Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07238322

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

View on ClinicalTrials.gov

Summary

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Official title: An Assessment of the Efficacy of Floretyrosine F 18 ([18F]FET) Positron Emission Tomography (PET) for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

400

Start Date

2025-09-22

Completion Date

2026-02-23

Last Updated

2026-02-20

Healthy Volunteers

Not specified

Interventions

DIAGNOSTIC_TEST

18F(FET)PET

Imaging as part of routine care

Locations (4)

University of California, San Francisco

San Francisco, California, United States

University Hospital Essen

Essen, Germany

Universityhospital Tuebingen

Tübingen, Germany

The University Medical Center Utrecht

Utrecht, Netherlands